Zobrazeno 1 - 10
of 10
pro vyhledávání: '"John-Paul Vermitsky"'
Autor:
Thomas D. Edlind, Kelley R. Healey, Santosh K. Katiyar, John-Paul Vermitsky, Celeste Shelton, Eric Shiffrin
Publikováno v:
Journal of Clinical Microbiology. 54:1042-1050
The opportunistic yeast Candida glabrata is increasingly refractory to antifungal treatment or prophylaxis and relatedly is increasingly implicated in health care-associated infections. To elucidate the epidemiology of these infections, strain typing
Autor:
John-Paul Vermitsky, Scott E. Gygax, Kelly E. Caudle, Sean G. Chadwick, P. David Rogers, Sarah G. Whaley, Geoffrey Toner, Katherine S. Barker
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:4543-4554
Candida glabrata , the second most common cause of Candida infections, is associated with high rates of mortality and often exhibits resistance to the azole class of antifungal agents. Upc2 and Ecm22 in Saccharomyces cerevisiae and Upc2 in Candida al
Autor:
Santosh K. Katiyar, Geoffrey Toner, Thomas D. Edlind, John-Paul Vermitsky, Zoë Steier, Scott E. Gygax
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:5543-5547
Infections with the opportunistic yeast Candida glabrata have increased dramatically in recent years. Antifungal therapy of yeast infections commonly employs azoles, such as fluconazole (FLC), but C. glabrata frequently develops resistance to these i
Autor:
Scott E. Gygax, Martin E. Adelson, Eli Mordechai, John-Paul Vermitsky, Jessica A. Schuyler, Sean G. Chadwick
Publikováno v:
Journal of Medical Microbiology. 62:720-726
Candida species are responsible for many opportunistic fungal infections. Fluconazole is a well-tolerated antifungal drug, commonly used in the treatment of candidiasis. However, with fluconazole resistance ever increasing, rapid detection and antifu
Autor:
John-Paul Vermitsky, Ramin Homayouni, P. David Rogers, W. Lamar Smith, Thomas D. Edlind, Kelly D. Earhart
Publikováno v:
Molecular Microbiology. 61:704-722
Candida glabrata emerged in the last decade as a common cause of mucosal and invasive fungal infection, in large part due to its intrinsic or acquired resistance to azole antifungals such as fluconazole. In C. glabrata clinical isolates, the predomin
Publikováno v:
Journal of Antimicrobial Chemotherapy. 58:434-438
Objectives: The aim of the present study was to identify changes in the proteome of a laboratory-derived azole-resistant strain of Candida glabrata compared with its susceptible parent strain in an effort to identify proteins that are differentially
Autor:
John-Paul Vermitsky, Thomas D. Edlind
Publikováno v:
Antimicrobial Agents and Chemotherapy. 48:3773-3781
Candida glabrata has emerged as a common cause of fungal infection. This yeast has intrinsically low susceptibility to azole antifungals such as fluconazole, and mutation to frank azole resistance during treatment has been documented. Potential resis
Autor:
Eli Mordechai, Scott E. Gygax, Jason P. Trama, Martin E. Adelson, John-Paul Vermitsky, Jessica A. Zimmerman, Sean G. Chadwick, Matthew J. Self
Publikováno v:
Antimicrobial agents and chemotherapy. 52(9)
A multiplex quantitative reverse transcription-PCR assay was developed to detect azole resistance in Candida glabrata, an important opportunistic pathogen that develops resistance rapidly. Resistance was defined as a >3-fold increase in CDR1 expressi
Autor:
Jason P. Trama, Sean G. Chadwick, Matthew J. Self, Scott E. Gygax, Eli Mordechai, Martin E. Adelson, John-Paul Vermitsky
Publikováno v:
Journal of clinical microbiology. 46(4)
A retrospective survey of 93,775 samples testing positive in Candida species-specific PCR tests performed on cervicovaginal swabs over a 4-year period demonstrated consistent yearly distributions of Candida albicans (89%), C. glabrata (7.9%), C. para
Autor:
Karl W. Henry, Thomas D. Edlind, Santosh K. Katiyar, John-Paul Vermitsky, Merritt P. Edlind, Shriya Raj
Publikováno v:
Current genetics. 48(2)
PCR product-based gene disruption has greatly accelerated molecular analysis of Saccharomyces cerevisiae. This approach involves amplification of a marker gene (e.g., URA3) including its flanking regulatory (promoter and polyadenylation) regions usin